- Home
- LYRA vs INAB Comparison
LYRA vs INAB Comparison
Compare LYRA & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- INAB
- Stock Information
- Founded
- LYRA 2005
- INAB 2016
- Country
- LYRA United States
- INAB United States
- Employees
- LYRA N/A
- INAB N/A
- Industry
- LYRA Medical/Dental Instruments
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- LYRA Health Care
- INAB Health Care
- Exchange
- LYRA Nasdaq
- INAB Nasdaq
- Market Cap
- LYRA 15.0M
- INAB 14.5M
- IPO Year
- LYRA 2020
- INAB 2021
- Fundamental
- Price
- LYRA $7.95
- INAB $2.44
- Analyst Decision
- LYRA Buy
- INAB Strong Buy
- Analyst Count
- LYRA 2
- INAB 2
- Target Price
- LYRA $16.00
- INAB $108.00
- AVG Volume (30 Days)
- LYRA 91.5K
- INAB 146.4K
- Earning Date
- LYRA 08-13-2025
- INAB 08-07-2025
- Dividend Yield
- LYRA N/A
- INAB N/A
- EPS Growth
- LYRA N/A
- INAB N/A
- EPS
- LYRA N/A
- INAB N/A
- Revenue
- LYRA $1,185,000.00
- INAB N/A
- Revenue This Year
- LYRA N/A
- INAB N/A
- Revenue Next Year
- LYRA $139.18
- INAB N/A
- P/E Ratio
- LYRA N/A
- INAB N/A
- Revenue Growth
- LYRA N/A
- INAB N/A
- 52 Week Low
- LYRA $3.81
- INAB $2.05
- 52 Week High
- LYRA $37.50
- INAB $26.76
- Technical
- Relative Strength Index (RSI)
- LYRA 41.08
- INAB 48.87
- Support Level
- LYRA $7.77
- INAB $2.13
- Resistance Level
- LYRA $8.67
- INAB $2.49
- Average True Range (ATR)
- LYRA 0.45
- INAB 0.14
- MACD
- LYRA -0.03
- INAB 0.09
- Stochastic Oscillator
- LYRA 11.32
- INAB 77.29
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.